177 Lu-FAP-2286 Combined Chemotherapy in a Case of Thymus Nonkeratinizing Squamous Carcinoma With Superior Vena Cava Syndrome

Clin Nucl Med. 2026 Jun 1;51(6):509-510. doi: 10.1097/RLU.0000000000006350. Epub 2026 Feb 3.

Abstract

We reported a 52-year-old man with thymus nonkeratinized squamous carcinoma presenting with acute superior vena cava syndrome (SVCS) who received 177 Lu-FAP-2286 treatment and followed by low-dose chemotherapy. 68 Ga-FAP-2286 PET/CT revealed significantly less intensity of the mediastinal mass comparing to pretherapy scan, as well as significant relief of SVCS. No adverse effects were observed.

Keywords: fibroblast activation protein; nonkeratinized squamous cell carcinoma; radionuclide therapy; superior vena cava syndrome.

Publication types

  • Case Reports

MeSH terms

  • Benzamides* / therapeutic use
  • Carcinoma, Squamous Cell* / complications
  • Carcinoma, Squamous Cell* / diagnostic imaging
  • Carcinoma, Squamous Cell* / drug therapy
  • Humans
  • Keratins / metabolism
  • Lutetium* / therapeutic use
  • Male
  • Middle Aged
  • Oligopeptides* / therapeutic use
  • Positron Emission Tomography Computed Tomography
  • Radioisotopes / therapeutic use
  • Superior Vena Cava Syndrome* / complications
  • Superior Vena Cava Syndrome* / diagnostic imaging
  • Thymus Neoplasms* / complications
  • Thymus Neoplasms* / diagnostic imaging
  • Thymus Neoplasms* / drug therapy

Substances

  • Lutetium
  • Benzamides
  • Lutetium-177
  • Radioisotopes
  • Keratins
  • Oligopeptides